REPORTABLE CASES – MISSISSIPPI For cases diagnosed 10/1/2018 and after

The following lists are intended to assist you, as the reporter, in identifying the reportable neoplasms for your facility. Any reportable neoplasms diagnosed on or after January 1, 1996 should be reported to the Mississippi Cancer Registry.

REPORTABLE NEOPLASMS

- Malignant neoplasms (exclusions noted below)
- Benign and borderline neoplasms of the central nervous system (Cases diagnosed on or after January 1, 2004)
- Pilocytic/juvenile astrocytoma listed as 9421/1 in ICD-O-3, is reportable, and should be coded to 9421/3.
- Squamous intraepithelial neoplasia grade III of vulva [VIN], vagina [VAIN], and anus [AIN] beginning with 2001 cases.
- Carcinoid, NOS of the appendix is reportable and should be coded 8240/3 (Cases diagnosed on or after January 1, 2015)
- Gastrointestinal Stromal Tumor (GIST), NOS with multiple tumor foci and/or metastasis to lymph nodes or distant sites.
- Thymoma, NOS with multiple tumor foci and/or metastasis to lymph nodes or distant sites.
- Malignant GIST and malignant thymomas
- Solid pseudopapillary neoplasm of the pancreas (8452/3) (Cases diagnosed on or after January 1, 2015)
- Cystic pancreatic endocrine neoplasm (CPEN) (8150/3), unless the tumor is specified as a neuroendocrine tumor, grade 1 (assign code 8240/3) or neuroendocrine tumor, grade 2 (assign code 8249/3) (For cases diagnosed January 1, 2015 or later)
- Laryngeal intraepithelia1 neoplasia, grade III (LINIII) (8077/2) (C320-C329) (For cases diagnosed January 1, 2015 or later)
- Squamous intraepithelia1 neoplasia, grade III (SIN III) (8077/2), except cervix and skin (For cases diagnosed January 1, 2015 and later)
- Mature teratoma of the testes in adults (9080/3) (For cases diagnosed January 1, 2015 and later)

NON-REPORTABLE NEOPLASMS

- Basal and squamous cell carcinomas of the skin (ICD-O-3 Histologies 8090-8110)
- Epithelial carcinomas of the skin (ICD-O-3 Histologies 8010-8046)
- Papillary and squamous cell carcinomas of the skin (ICD-O-3 Histologies 8050-8084)
- Malignant neoplasms, NOS of the skin (ICD-O-3 Histologies 8000-8005)
- Carcinoma in-situ of the cervix

- Intraepithelial neoplasms of the cervix (ICD-O-3 Histology 8077/2) or prostate (ICD-O-3 Histology 8148/2)
- Borderline cystadenomas (ICD-O-3 Histologies 8442, 8451, 8462, 8472, 8473), of the ovaries with behavior code "1" are **not** collected as of January 1, 2001
- Cyst, brain or CNS tumor that does not have an ICD-O-3 code as of January 1, 2004
- Gastrointestinal Stromal Tumor (GIST), NOS that are not stated to be malignant and are a single tumor with no metastasis to nodes or distant sites
- Thymoma, NOS that are not stated to be malignant and are a single tumor with no metastasis to nodes or distant sites
- Severe dysplasia of any site including the Gastrointestinal Tract. There must be a statement that this is carcinoma in situ to be reportable.
- Mature teratoma of the testes in prepubescent children (9080/0)

| Terms That Constitute a Diagnosis** | Terms That Do Not Constitute a |
|------------------------------------------|--------------------------------|
| | Diagnosis |
| Apparent(ly) | Cannot be ruled out |
| Appears to | Equivocal |
| Comparable with | Possible |
| Compatible with | Potentially malignant |
| Consistent with | Questionable |
| Favor(s) | Rule out |
| Malignant appearing | Suggests |
| Most likely | Worrisome |
| Presumed | |
| Probable | |
| Suspect | |
| Suspicious | |
| Typical of | |
| Tumor (beginning with 2004 diagnosis and | |
| only for C70.0-C72.9, C75.1-C75.3) | |
| Neoplasm (beginning with 2004 diagnosis | |
| and only for C70.0-C72.9, C75.1-C75.3) | |

AMBIGUOUS TERMINOLOGY

** Do not substitute synonyms such as "supposed" for "presumed" or "equal" for "comparable." Do not substitute "likely" for "most likely." Use on the exact words on the list.

Exceptions:

- If a cytology is reported using any ambiguous term, do not interpret it as a diagnosis of cancer. Abstract the case only if a positive biopsy or a physician's clinical impression of cancer supports the cytology findings.
- Genetic findings in the absence of pathologic or clinical evidence of reportable disease are indicative of risk only and do not constitute a diagnosis.

COMPREHENSIVE ICD-10-CM CASEFINDING CODE LIST FOR REPORTABLE TUMORS

| ICD-10-CM Codes | Explanation of Codes |
|------------------|-------------------------------------------------------------------------|
| C00C43, | Malignant neoplasms (excluding category C44 and C49.A), stated |
| C4A, C45 | or presumed to be primary (of specified site) and certain specified |
| C48, C49 | histologies ¹ |
| C96 | NEW for 2018: |
| | C96.20 Malignant mast cell neoplasm, unspecified |
| | C96.21 Aggressive systemic mastocytosis |
| | C96.22 mast cell sarcoma |
| | C96.29 Other malignant cell neoplasm |
| C44.00, C44.09 | Unspecified/other malignant neoplasm of skin of lip |
| C44.10_, C44.19_ | Unspecified/other malignant neoplasm of skin of eyelid |
| C44.20_, C44.29_ | Unspecified/other malignant neoplasm skin of ear and external |
| | auricular canal |
| C44.30_, C44.39_ | Unspecified/other malignant neoplasm of skin of other/unspecified |
| | parts of face |
| C44.40, C44.49 | Unspecified/other malignant neoplasm of skin of scalp & neck |
| C44.50_, C44.59_ | Unspecified/other malignant neoplasm of skin of trunk |
| C44.60_, C44.69_ | Unspecified/other malignant neoplasm of skin of upper limb, incl. |
| | shoulder |
| C44.70_, C44.79_ | Unspecified/other malignant neoplasm of skin of lower limb, |
| | including hip |
| C44.80, C44.89 | Unspecified/other malignant neoplasm of skin of overlapping sites |
| | of skin |
| C44.90, C44.99 | Unspecified/other malignant neoplasm of skin of unspecified sites |
| | of skin |
| C49.A_ | Gastrointestinal Stromal Tumors |
| | Note: GIST is only reportable when it is malignant (/3). GIST, |
| | NOS (not stated whether malignant or benign) is a $/1$ and is not |
| | reportable. |
| D00 D09 | In-situ neoplasms (Note: Carcinoma in situ of the cervix (CIN III- |
| | 8077/2) and Prostatic Intraepithelial Carcinoma (PIN III-8148/2) |
| D 10.02 | are not reportable). |
| D18.02 | Hemangioma of intracranial structures and any site |
| D18.1 | Lymphangioma, any site (Note: Includes Lymphangiomas of |
| | Brain, Other parts of nervous system and endocrine glands, which |
| D22 | are reportable) |
| D32 | Benign neoplasm of meninges (cerebral, spinal and unspecified) |
| D33 | Benign neoplasm of brain and other parts of central nervous |
| D35.2 - D35.4 | system Benign neoplasm of pituitary gland, craniopharyngeal duct and |
| D35.2 - D35.4 | pineal gland |
| D42, D43 | Neoplasm of uncertain or unknown behavior of meninges, brain, |
| D+2, D+3 | CNS |
| | |

| ICD-10-CM Codes | Explanation of Codes |
|-----------------|-----------------------------------------------------------------|
| D44.3 – D44.5 | Neoplasm of uncertain or unknown behavior of pituitary gland, |
| | craniopharyngeal duct and pineal gland |
| D45 | Polycythemia vera (9950/3) |
| D46 | Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, |
| | 9991, 9992) |
| D47.1 | Chronic myeloproliferative disease (9960/3, 9963/3) |
| D47.3 | Essential (hemorrhagic) thrombocythemia (9962/3) |
| D47.4 | Osteomyelofibrosis (9961/3) |
| | Includes: Chronic idiopathic myelofibrosis, Myelofibrosis |
| | (idiopathic) (with myeloid metaplasia), myelosclerosis |
| | (megakaryocytic) with myeloid metaplasia), secondary |
| | myelofibrosis in myeloproliferative disease |
| D47.Z_ | Neoplasm of uncertain behavior of lymphoid, hematopoietic and |
| | related tissue, unspecified (9960/3, 9970/1, 9931/3) |
| D47.9 | Neoplasm of uncertain behavior of lymphoid, hematopoietic and |
| | related tissue, unspecified (9931/3) |
| D49.6, D49.7 | Neoplasm of unspecified behavior of brain, endocrine glands and |
| | other CNS |
| R85.614 | Cytologic evidence of malignancy on smear of anus |
| R87.614 | Cytologic evidence of malignancy on smear of cervix |
| R87.624 | Cytologic evidence of malignancy on smear of vagina |

¹ Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, these cases should be reported and behavior coded as /3 (malignant).

SUPPLEMENTAL CASEFINDING LIST TO BE SCREENED FOR REPORTABLE CONDITIONS

Cases with the following codes should be screened <u>as time allows</u>. Experience has shown that use of this supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms and other reportable diseases

| ICD-10-CM Codes | Explanation of Codes |
|------------------|----------------------------------------------------------------|
| B20 | Human immunodeficiency virus [HIV] disease with other diseases |
| | Note: Excludes HIV with malignancy (B21), see reportable list |
| B97.33, B97.34, | Human T-cell lymphotrophic virus,(type I [HTLV-1], type II |
| B97.35 | [HTLV-II], type 2 [HIV 2]) as the cause of diseases classified |
| | elsewhere |
| B97.7 | Papillomarvirus as the cause of diseases classified elsewhere |
| C44.01, C44.02 | Basal/squamous cell carcinoma of skin of lip |
| C44.11_, C44.12_ | Basal/squamous cell carcinoma of skin of eyelid |
| C44.21_, C44.22_ | Basal/squamous cell carcinoma of skin of ear and external |
| | auricular canal |
| C44.31_, C44.32_ | Basal/squamous cell carcinoma of skin of other and unspecified |
| | parts of face |

| ICD-10-CM Codes | Explanation of Codes |
|------------------|------------------------------------------------------------------------------|
| C44.41, C44.42 | Basal/squamous cell carcinoma of skin of scalp and neck |
| C44.51_, C44.52_ | Basal/squamous cell carcinoma of skin of trunk |
| C44.61_, C44.62_ | Basal/squamous cell carcinoma of skin of upper limb, including |
| | shoulder |
| | |
| C44.71_, C44.72_ | Basal/squamous cell carcinoma of skin of lower limb, including |
| | hip |
| C44.81, C44.82 | Basal/squamous cell carcinoma of skin of overlapping sites of skin |
| C44.91, C44.92 | Basal/squamous cell carcinoma of skin of unspecified sites of skin |
| D10 – D31, | Benign neoplasms (see "must collect" list for reportable benign |
| D34, D35.0, | neoplasms) |
| D35.1, D35.5_ | Note: Screen for incorrectly coded |
| D35.9, D36 | |
| D3A | Benign carcinoid tumors |
| D37 – D41 | Neoplasms of uncertain or unknown behavior (see "must collect" |
| | list for reportable neoplasms of uncertain or unknown behavior) |
| D44.0 D44.0 | Note: Screen for incorrectly coded malignancies |
| D44.0 – D44.2, | Neoplasm of uncertain or unknown behavior of other endocrine |
| D44.6-D44.9 | glands (see "must collect" list for D44.3-D44.5) |
| D 47 01 | Note: Screen for incorrectly coded malignancies |
| D47.01 | Cutaneous mastocytosis (9740/1) |
| C 17.00 | <i>Note:</i> Effective 10/1/2017 |
| C47.09 | Other mast cell neoplasms of uncertain behavior Note: Effective 10/1/2017 |
| D47.2 | Monoclonal gammopathy |
| D47.2 | Note: Screen for incorrectly coded Waldenstrom's |
| | macroglobulinemia |
| D47.Z2 | Castleman disease |
| D48 | Neoplasm of uncertain behavior of other and unspecified sites |
| D49.0 – D49.9 | Neoplasm of unspecified behavior (except for D49.6 and D49.7) |
| D61.1 | Drug-induced aplastic anemia (also known as "aplastic anemia due |
| 2 0111 | to antineoplastic chemotherapy") |
| D61.810 | Anemia due to antineoplastic chemotherapy |
| D61.82 | Myelophthisis |
| D63.0 | Anemia in neoplastic disease |
| D64.81 | Anemia due to antineoplastic chemotherapy |
| D69.49, D69.59, | Other thrombocytopenia |
| D69.6 | Note: Screen for incorrectly coded thrombocythemia |
| D70.1 | Agranulocytosis secondary to cancer chemotherapy |
| D72.1 | Eosinophilia (Note: Code for eosinophilia (9964/3). Not every case |
| | of eosinophilia is a malignancy. Reportable Diagnosis is |
| | "Hypereosonophilic syndrome.") |
| D75.81 | Myelofibrosis (note: this is not primary myelofibrosis [9961/3]) |
| D76 | Other specified diseases with participation of lymphoreticular and |
| | reticulohistiocytic tissue |

| ICD-10-CM CodesExplanation of CodesD89.0, D89.1Other disorders involving the immune mechanism, not elsew classified Note: Review for miscodesD89.4_Mast cell activation syndrome and related disorders Note: effective 10/1/2016E08Diabetes mellitus due to underlying conditionE31.2_Multiple endocrine neoplasia [MEN] syndromesE34.0Carcinoid syndromeE83.52HypercalcemiaE88.09Other disorders of plasma-protein metabolism, not elsewhere classifiedE88.3Tumor lysis syndrome (following antineoplastic chemotherap G13.1G13.1Other systemic atrophy primarily affecting central nervous sy | here |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| classified Note: Review for miscodesD89.4_Mast cell activation syndrome and related disorders Note: effective 10/1/2016E08Diabetes mellitus due to underlying conditionE31.2_Multiple endocrine neoplasia [MEN] syndromesE34.0Carcinoid syndromeE83.52HypercalcemiaE88.09Other disorders of plasma-protein metabolism, not elsewhere classifiedE88.3Tumor lysis syndrome (following antineoplastic chemotherap G13.0 | |
| Note: Review for miscodesD89.4_Mast cell activation syndrome and related disorders Note: effective 10/1/2016E08Diabetes mellitus due to underlying conditionE31.2_Multiple endocrine neoplasia [MEN] syndromesE34.0Carcinoid syndromeE83.52HypercalcemiaE88.09Other disorders of plasma-protein metabolism, not elsewhere classifiedE88.3Tumor lysis syndrome (following antineoplastic chemotherap G13.0 | |
| D89.4_Mast cell activation syndrome and related disorders Note: effective 10/1/2016E08Diabetes mellitus due to underlying conditionE31.2_Multiple endocrine neoplasia [MEN] syndromesE34.0Carcinoid syndromeE83.52HypercalcemiaE88.09Other disorders of plasma-protein metabolism, not elsewhere classifiedE88.3Tumor lysis syndrome (following antineoplastic chemotherap G13.0 | |
| Note: effective 10/1/2016E08Diabetes mellitus due to underlying conditionE31.2_Multiple endocrine neoplasia [MEN] syndromesE34.0Carcinoid syndromeE83.52HypercalcemiaE88.09Other disorders of plasma-protein metabolism, not elsewhere classifiedE88.3Tumor lysis syndrome (following antineoplastic chemotherap G13.0G13.0Paraneoplastic neuromyopathy and neuropathy | |
| E08Diabetes mellitus due to underlying conditionE31.2_Multiple endocrine neoplasia [MEN] syndromesE34.0Carcinoid syndromeE83.52HypercalcemiaE88.09Other disorders of plasma-protein metabolism, not elsewhere classifiedE88.3Tumor lysis syndrome (following antineoplastic chemotherap G13.0G13.0Paraneoplastic neuromyopathy and neuropathy | |
| E31.2_Multiple endocrine neoplasia [MEN] syndromesE34.0Carcinoid syndromeE83.52HypercalcemiaE88.09Other disorders of plasma-protein metabolism, not elsewhere classifiedE88.3Tumor lysis syndrome (following antineoplastic chemotherap G13.0G13.0Paraneoplastic neuromyopathy and neuropathy | |
| E83.52HypercalcemiaE88.09Other disorders of plasma-protein metabolism, not elsewhere classifiedE88.3Tumor lysis syndrome (following antineoplastic chemotherap G13.0G13.0Paraneoplastic neuromyopathy and neuropathy | |
| E88.09Other disorders of plasma-protein metabolism, not elsewhere classifiedE88.3Tumor lysis syndrome (following antineoplastic chemotherap G13.0G13.0Paraneoplastic neuromyopathy and neuropathy | |
| classifiedE88.3Tumor lysis syndrome (following antineoplastic chemotherapG13.0Paraneoplastic neuromyopathy and neuropathy | |
| E88.3Tumor lysis syndrome (following antineoplastic chemotherapG13.0Paraneoplastic neuromyopathy and neuropathy | |
| G13.0 Paraneoplastic neuromyopathy and neuropathy | |
| | y) |
| G13.1 Other systemic atrophy primarily affecting central nervous sy | |
| | rstem |
| in neoplastic disease | |
| G32.8 Other specified degenerative disorders of nervous system in | |
| diseases classified elsewhere | |
| G53 Cranial nerve disorders in diseases classified elsewhere | |
| Note: Code first underlying neoplasm (C00-D49) | |
| G55 Nerve root and plexus compressions in diseases classified | |
| elsewhere | |
| ICD-10-CM Coding instruction note: code also underlying di | sease, |
| such as neoplasm (C00-D49) | |
| G63 Polyneuropathy in diseases classified elsewhere | |
| G73.1 Lambert-Eaton syndrome in neoplastic disease | |
| G89.3 Neoplasm related pain (acute)(chronic) | |
| G99.2 Myelopathy in disease classified elsewhere | |
| H47.42 Disorders of optic chiasms in (due to) neoplasm | |
| H47.52 Disorders of visual pathways in (due to) neoplasm | |
| H47.63_Diorders of visual cortex in (due to) neoplasmJ34.81Nasal mucositis (ulcerative) | |
| J34.81Nasai Indeositis (deerative)J91.0Malignant pleural effusion | |
| J91.0Ivialgnant pieurar errusionJ93.12Secondary spontaneous pneumothorax | |
| Secondary spontaneous pneumonioraxK12.31Oral mucositis (ulcerative) due to antineoplastic therapy | |
| K12.31Oral nucositis (ucerative) due to antineoplastic unerapyK12.33Oral nucositis (ucerative) due to radiation | |
| K12.35Oral indeositis (decrative) due to radiationK22.711Barrett's esophagus with high grade dysplasia | |
| K22.711Darrett's esophagus with high grade dysplasiaK62.7Radiation proctitis | |
| K62.82Dysplasia of anus (AIN I and AIN II) | |
| K02.02Dysplasta of ands (ATA F and ATA A)K92.81Gastrointestinal mucositis (ulcerated) (due to antineoplastic | |
| therapy) | |
| M36.0 Dermato(poly)myositis in neoplastic disease | |
| M36.1 Arthropathy in neoplastic disease | |
| M84.5_ Pathologic fracture in neoplastic disease | |
| M90.6_ Osteitis deformans in neoplastic disease | |
| N42.3 Dysplasia of prostate (PIN I and PIN II) | |

| ICD-10-CM Codes | Explanation of Codes |
|-------------------|-----------------------------------------------------------------------|
| N76.81 | Mucositis (ulcerative) of vagina or vulva |
| N87 | Dysplasia of cervix uteri (CIN I and CIN II) |
| N89.0, N89.1, | Vaginal dysplasia (VIN I and VIN II) |
| N89.3 | |
| N90.0, N90.1, | Vulvar dysplasia (VAIN I and VAIN II) |
| N90.3 | |
| 001 | Hydatidiform mole Note: Benign tumor that can become |
| | malignant. If malignant, report as Choriocarcinoma (9100/3,) |
| | malignancy code in the C00- C97 range |
| O9A.1_ | Malignant neoplasm complicating pregnancy, childbirth and the |
| 0)/III_ | puerperium |
| P04.11 | Newborn affected by maternal antineoplastic chemotherapy |
| 10001 | Note: Effective 10/1/2018 |
| P04.12 | Newborn affected by maternal cytotoxic drugs |
| 10112 | Note: Effective 10/1/2018 |
| Q85.0_ | Neurofibromatosis (nonmalignant) (9540/1) |
| | Note: Neurofibromatosis is not cancer. These tumors can be |
| | precursors to acoustic neuromas, which are reportable |
| R18.0 | Malignant ascites |
| R53.0 | Neoplastic (malignant) related fatigue |
| R59 | Enlarged lymph nodes |
| R85.6_ | Abnormal findings on cytological and histological examination of |
| 10010_ | digestive organs |
| R87.61_, R87.62_ | Abnormal findings on cytological/histological examination of |
| | female genital organs |
| R92 | Abnormal findings on diagnostic imaging of breast |
| R97 | Abnormal tumor markers |
| T38.6_ | Poisoning by antigonadotropins, antiestrogens, antiandrogens, not |
| | elsewhere classified |
| T38.8_, T38.9_ | Poisoning by hormones and their synthetic substitutes |
| | Poisoning by, adverse effect of and under dosing of antineoplastic |
| | and immunosuppressive drugs |
| T45.8_, T45.9_ | Poisoning by primary systemic and hematological agent, |
| _/ _ | unspecified |
| T66 | Unspecified effects of radiation |
| T80.1 | Vascular complications following infusion, transfusion and |
| | therapeutic injection |
| T80.2_ | Infections following infusion, transfusion and therapeutic injection |
| T80.810 | Extravasation of vesicant antineoplastic chemotherapy |
| T80.818 | Extravasation of other vesicant agent |
| T86.0 | Complications of bone marrow transplant |
| Y63.2 | Overdose of radiation given during therapy |
| Y84.2 | Radiological procedure and radiotherapy as the cause of abnormal |
| | reaction of the patient, or of later complication, without mention of |
| | misadventure at the time of the procedure |
| | L |

| ICD-10-CM Codes | Explanation of Codes |
|------------------|--------------------------------------------------------------------|
| Z03.89 | Encounter for observation for other suspected diseases and |
| | conditions ruled out |
| Z08 | Encounter for follow-up examination after completed treatment for |
| | malignant neoplasm |
| Z12 | Encounter for screening for malignant neoplasms |
| Z13.0 | Encounter of screening for diseases of the blood and blood- |
| | forming organs and certain disorders involving the immune |
| | mechanism |
| Z15.0 | Genetic susceptibility to malignant neoplasm |
| Z17.0, Z17.1 | Estrogen receptor positive and negative status |
| Z40.0_ | Encounter for prophylactic surgery for risk factors related to |
| | malignant neoplasms |
| Z42.1 | Encounter for breast reconstruction following mastectomy |
| Z48.290 | Encounter for aftercare following bone marrow transplant |
| Z48.3 | Aftercare following care for neoplasm |
| Z51.0 | Encounter for antineoplastic radiation therapy |
| Z51.1_ | Encounter for antineoplastic chemotherapy and immunotherapy |
| Z51.5, Z51.89 | Encounter for palliative care and other specified aftercare |
| Z79.81_ | Long term (current) use of agents affecting estrogen receptors and |
| | estrogen levels |
| Z80 | Family history of primary malignant neoplasm |
| Z85 | Personal history of malignant neoplasm |
| Z86.0_, Z86.01_, | Personal history of in situ and benign neoplasms and neoplasms of |
| Z86.03 | uncertain behavior |
| Z92.21, Z29.23, | Personal history of antineoplastic chemotherapy, estrogen therapy, |
| Z92.25. Z92.3 | immunosuppression therapy or irradiation (radiation) |
| Z94.81, Z94.84 | Bone marrow and stem cell transplant status |